Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company developing advanc...
UroGen Pharma Ltd. is a clinical-stage biopharm...
Titan is a specialty pharmaceuticals company that develops therapeutics for select...
Titan is a specialty pharmaceuticals company th...
BioSig Technologies is a medical device company developing a proprietary technolog...
BioSig Technologies is a medical device company...
Corcept is a pharmaceutical company engaged in the discovery, development and comm...
Corcept is a pharmaceutical company engaged in ...
Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on...
Outlook Therapeutics is a late clinical-stage b...
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology comp...
Amicus Therapeutics (Nasdaq: FOLD) is a global,...
Benitec is a biotechnology company developing a proprietary therapeutic technology...
Benitec is a biotechnology company developing a...
Join the National Investor Network and get the latest information with your interests in mind.